Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations

被引:0
作者
Ahsan S. Farooqi
Rebecca A. Dagg
L. Mi Rim Choi
Jerry W. Shay
C. Patrick Reynolds
Loretta M. S. Lau
机构
[1] Texas Tech University Health Sciences Center,Cancer Center, Department of Cell Biology and Biochemistry
[2] Texas Tech University Health Sciences Center,Department of Pharmacology
[3] Texas Tech University Health Sciences Center,Department of Internal Medicine
[4] Texas Tech University Health Sciences Center,Department of Pediatrics, School of Medicine
[5] The Children’s Hospital at Westmead,Children’s Cancer Research Unit, Kids Research Institute
[6] Spectrum Pharmaceuticals,Department of Cell Biology, Southwestern Medical Center
[7] Inc.,Center of Excellence in Genomic Medicine Research
[8] University of Texas,Discipline of Paediatrics and Child Health, Sydney Medical School
[9] King Abdulaziz University,undefined
[10] University of Sydney,undefined
来源
Journal of Neuro-Oncology | 2014年 / 119卷
关键词
Neuroblastoma; Telomere; Telomerase; ALT; p53; ATRX;
D O I
暂无
中图分类号
学科分类号
摘要
Alternative lengthening of telomeres (ALT) is a telomerase-independent telomere length maintenance mechanism that enables the unlimited proliferation of a subset of cancer cells. Some neuroblastoma (NB) tumors appear to maintain telomere length by activating ALT. Of 40 NB cell lines, we identified four potential ALT cell lines (CHLA-90, SK-N-FI, LA-N-6, and COG-N-291) that were telomerase-negative and had long telomeres (a feature of ALT cells). All four cell lines lacked MYCN amplification and were p53 non-functional upon irradiation. Two of these cell lines (CHLA-90 and SK-N-FI) were positive for C-circles (telomeric DNA circles) and ALT-associated promyelocytic leukemia nuclear bodies, both of which are phenotypic characteristics of ALT. Mutation of ATRX (associated with ALT in tumors) was only found in CHLA-90. Thus, the ALT phenotype in NB may not be limited to tumors with ATRX mutations but is associated with a lack of MYCN amplification and alterations in the p53 pathway.
引用
收藏
页码:17 / 26
页数:9
相关论文
共 432 条
  • [21] Prowse KR(2013)The genetic landscape of high-risk neuroblastoma Nat Genet 45 279-2120
  • [22] Harley CB(2007)Neuroblastoma Lancet 369 2106-2266
  • [23] West MD(2009)Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres J Pediatr Surg 44 2258-1482
  • [24] Ho PL(2011)Alternative lengthening of telomeres-An enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas Genes Chromosomes Cancer 100 1471-306
  • [25] Coviello GM(2009)International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee Br J Cancer 271 291-5405
  • [26] Wright WE(1988)Biological classification of cell lines derived from human extra-cranial neural tumors Prog Clin Biol Res 58 5396-6193
  • [27] Weinrich SL(1998)Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy Cancer Res 61 6185-8017
  • [28] Shay JW(2001)Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines Cancer Res 98 8012-949
  • [29] Bryan TM(2001)Short tandem repeat profiling provides an international reference standard for human cell lines Proc Natl Acad Sci USA 41 e34-3875
  • [30] Englezou A(2013)Detection of alternative lengthening of telomeres by telomere quantitative PCR Nucleic Acids Res 46 936-3502